Morris H, Wallach J (July–August 2014). «From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs». Drug Testing and Analysis6 (7–8): 614-32. PMID24678061. doi:10.1002/dta.1620.
Meyer MR, Orschiedt T, Maurer HH (February 2013). «Michaelis-Menten kinetic analysis of drugs of abuse to estimate their affinity to human P-glycoprotein». Toxicology Letters217 (2): 137-42. PMID23273999. doi:10.1016/j.toxlet.2012.12.012.
Wink CS, Meyer GM, Wissenbach DK, Jacobsen-Bauer A, Meyer MR, Maurer HH (October 2014). «Lefetamine-derived designer drugs N-ethyl-1,2-diphenylethylamine (NEDPA) and N-iso-propyl-1,2-diphenylethylamine (NPDPA): metabolism and detectability in rat urine using GC-MS, LC-MSn and LC-HR-MS/MS». Drug Testing and Analysis6 (10): 1038-48. PMID24591097. doi:10.1002/dta.1621.
Wink CS, Meyer GM, Meyer MR, Maurer HH (November 2015). «Toxicokinetics of lefetamine and derived diphenylethylamine designer drugs-Contribution of human cytochrome P450 isozymes to their main phase I metabolic steps». Toxicology Letters238 (3): 39-44. PMID26276083. doi:10.1016/j.toxlet.2015.08.012.
Berger ML, Schweifer A, Rebernik P, Hammerschmidt F (May 2009). «NMDA receptor affinities of 1,2-diphenylethylamine and 1-(1,2-diphenylethyl)piperidine enantiomers and of related compounds». Bioorganic & Medicinal Chemistry17 (9): 3456-62. PMID19345586. doi:10.1016/j.bmc.2009.03.025.
Goodson LH, Wiegand CJ, Splitter JS (November 1946). «Analgesics; n-alkylated-1,2-diphenylethylamines prepared by the Leuckart reaction». Journal of the American Chemical Society68 (11): 2174-2175. PMID21002222. doi:10.1021/ja01215a018.
Wink CS, Meyer GM, Zapp J, Maurer HH (February 2015). «Lefetamine, a controlled drug and pharmaceutical lead of new designer drugs: synthesis, metabolism, and detectability in urine and human liver preparations using GC-MS, LC-MS(n), and LC-high resolution-MS/MS». Analytical and Bioanalytical Chemistry407 (6): 1545-57. PMID25577353. doi:10.1007/s00216-014-8414-3.
Morris H, Wallach J (July–August 2014). «From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs». Drug Testing and Analysis6 (7–8): 614-32. PMID24678061. doi:10.1002/dta.1620.
Meyer MR, Orschiedt T, Maurer HH (February 2013). «Michaelis-Menten kinetic analysis of drugs of abuse to estimate their affinity to human P-glycoprotein». Toxicology Letters217 (2): 137-42. PMID23273999. doi:10.1016/j.toxlet.2012.12.012.
Wink CS, Meyer GM, Wissenbach DK, Jacobsen-Bauer A, Meyer MR, Maurer HH (October 2014). «Lefetamine-derived designer drugs N-ethyl-1,2-diphenylethylamine (NEDPA) and N-iso-propyl-1,2-diphenylethylamine (NPDPA): metabolism and detectability in rat urine using GC-MS, LC-MSn and LC-HR-MS/MS». Drug Testing and Analysis6 (10): 1038-48. PMID24591097. doi:10.1002/dta.1621.
Wink CS, Meyer GM, Meyer MR, Maurer HH (November 2015). «Toxicokinetics of lefetamine and derived diphenylethylamine designer drugs-Contribution of human cytochrome P450 isozymes to their main phase I metabolic steps». Toxicology Letters238 (3): 39-44. PMID26276083. doi:10.1016/j.toxlet.2015.08.012.
Berger ML, Schweifer A, Rebernik P, Hammerschmidt F (May 2009). «NMDA receptor affinities of 1,2-diphenylethylamine and 1-(1,2-diphenylethyl)piperidine enantiomers and of related compounds». Bioorganic & Medicinal Chemistry17 (9): 3456-62. PMID19345586. doi:10.1016/j.bmc.2009.03.025.
Goodson LH, Wiegand CJ, Splitter JS (November 1946). «Analgesics; n-alkylated-1,2-diphenylethylamines prepared by the Leuckart reaction». Journal of the American Chemical Society68 (11): 2174-2175. PMID21002222. doi:10.1021/ja01215a018.
Wink CS, Meyer GM, Zapp J, Maurer HH (February 2015). «Lefetamine, a controlled drug and pharmaceutical lead of new designer drugs: synthesis, metabolism, and detectability in urine and human liver preparations using GC-MS, LC-MS(n), and LC-high resolution-MS/MS». Analytical and Bioanalytical Chemistry407 (6): 1545-57. PMID25577353. doi:10.1007/s00216-014-8414-3.
